Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mycobacterium vaccae immunotherapy plus 4-month anti-tuberculosis regimen versus standard 6-month regimen in untreated smear-negative pulmonary tuberculosis
ChiCTR-TRC-14005160Phase 4Not yet recruiting
- Sponsor
- Chinese Center for Disease Control and Prevention
- Start
- Feb 2014
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of mycobacterium vaccae and standard anti-tuberculosis regimen in pulmonary tuberculosis (TB) (2 arms), sponsored by Chinese Center for Disease Control and Prevention. Primary endpoints: Absorption rate of lung lesions by chest X-ray, Incidence of adverse reactions and 3 more. Planned start Feb 2014; status: not yet recruiting.
02
Drugs
mycobacterium vaccaestandard anti-tuberculosis regimen
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on ChiCTR-TRC-14005160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-14005160.